EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial

Yanting Zou, Szu-Yuan Wu iD, Wanqin Zhang, Wei Zhang, Xizhong Shen, Xudong Qu iD, Qunyan Yao

Liver International · 2025-10 · 45 (10)

DOI: 10.1111/liv.70347 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Liver International, online erschienen am 17.09.2025. Verfasst von Yanting Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Polysaccharides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizontal Project in collaboration with Kelin Clinical Bioinformatics Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related mortality. Transarterial chemoembolization (TACE) is the standard locoregional therapy for unresectable HCC but is limited by high recurrence and hepatic toxicity. Low‐molecular‐weight fucoidan (LMF), a sulfated polysaccharide from brown seaweed, has anticancer and hepatoprotective properties. This study assessed whether LMF enhances tumour response and preserves liver function when combined with TACE.

Methods

In this randomised, double‐blind, placebo‐controlled trial, 82 patients with unresectable HCC were randomly assigned (1:1) to receive LMF (4.4 g twice daily) or placebo for 6 months in addition to TACE. Tumour response was assessed using modified RECIST criteria, and liver function was monitored via Child–Pugh classification. The primary endpoint was disease control rate (DCR), with objective response rate (ORR), liver function and adverse events as secondary endpoints.

Results

Baseline characteristics were well balanced. DCR was significantly higher in the LMF group (95.24% vs. 80.00%, p = 0.035), with a lower progressive disease rate (4.76% vs. 20.00%). ORR was higher in the LMF group (52.38% vs. 35.00%) but not statistically significant ( p = 0.1129). LMF preserved liver function ( p = 0.029), with more patients maintaining Child–Pugh Class A (80.95% vs. 62.50%). Adverse event rates were similar, and no severe adverse events occurred.

Conclusions

LMF improved tumour control, preserved liver function and had a favourable safety profile. These findings suggest LMF may mitigate TACE‐related hepatic toxicity and prolong treatment eligibility, warranting further validation in larger trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticPolysaccharidesAntineoplastic AgentsHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedTreatment OutcomeLiverLiver Function TestsAdult

Stichwörter der Autor:innen

disease control ratehepatocellular carcinomahepatoprotectionlow‐molecular‐weight fucoidantransarterial chemoembolization

Substanzen

fucoidanPolysaccharidesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
  • Shanghai Institute of Liver Diseases, Shanghai, China.
  • Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan.
  • Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan.
  • Center for Regional Anesthesia and Pain Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Szu-Yuan Wu, Xudong Qu

Förderung

  • Horizontal Project in collaboration with Kelin Clinical Bioinformatics Institute

Zitieren

APA

Zou, Y., Wu, S. Y., Zhang, W., Zhang, W., Shen, X., Qu, X., & Yao, Q. (2025). Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial. Liver International, 45(10). https://doi.org/10.1111/liv.70347

Vancouver

Zou Y, Wu SY, Zhang W, Zhang W, Shen X, Qu X, et al. Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial. Liver International. 2025;45(10). doi:10.1111/liv.70347

BibTeX
@article{Zou2025,
  author = {Zou, Yanting and Wu, Szu-Yuan and Zhang, Wanqin and Zhang, Wei and Shen, Xizhong and Qu, Xudong and Yao, Qunyan},
  title = {Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {10},
  doi = {10.1111/liv.70347}
}
Kostenlos starten →